Mabwell (SSE: 688062) is an innovation-driven biopharmaceutical company, has the whole industrial chain of R&D, manufacturing, and commercialization. We committed to provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established.
Clinical Trial Application for 7MW3711 - an Innovative Drug Developed by Mabwell's ADC Platform, Accepted by NMPA
Mabwell's First Self-commercialized Drug Reached its National Logistics Ceremony